Ocugen (OCGN)
(Real Time Quote from BATS)
$1.69 USD
-0.06 (-3.43%)
Updated May 28, 2024 10:48 AM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
Ocugen, Inc. [OCGN]
Reports for Purchase
Showing records 1 - 20 ( 121 total )
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Pipeline Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Showcase Highlights OCU400 Clinical Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Entering a Year of Execution; New $7 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Additional Clinical Data Strengthens Our Confidence in OCU400; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
OCU400 to Enter Phase 3 in Coming Months; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Focus Remains on Modifier Gene Therapy Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
1Q23: More OCU400 Phase 2 Data Phase 3 Start in 2023, 2 New INDs in 2Q23
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data At ARVO Demonstrate Promise of OCU200 OCU410/ OCU410ST
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
ARVO Highlights Recent OCU400 Clinical Data & New OCU410 Preclinical Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Initial Clinical Data Validates OCU400?s Potential as Modifier Gene Therapy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Reports Positive Phase 1 OCU400 Data in RP from Dose Cohorts 1 and 2
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
Company: Ocugen, Inc.
Industry: Medical - Biomedical and Genetics
FDA Allows Pediatric Enrollment In Ongoing OCU400 Phase 1/2 RP/LCA Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J